You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. The Antibody Registry: A Community Authority for Antibody Research Resource Identifiers

    SBC: SCICRUNCH            Topic: 300

    Project SummaryOne of the most glaring yet easily addressable gaps in our current scientific workflow and publication system is improving the way that methods are reportedin particularthe lack of key methodological details necessary for interpreting and reproducing a studyMost authors continue to cite the name of the reagentlike an antibody using the vendorand the city where the vendor is locatedb ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. BlueBox: A Complete Code Blue Data Recorder, Phase II

    SBC: NeoVative, Inc.            Topic: 400

    Code blueis the signal used in hospitals to call for an immediate cardiopulmonary resuscitationCPRfollowing a cardiac or respiratory arrestReviewing the performance of thecode blue teamis a cornerstone for improving outcomesThe current standard of using handwritten records on a papercode sheetdoes not allow measurement of key quality indicators and is subject to human errorIn the Phase I STTR proj ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Developing a Nutraceutical Product against Ototoxicity

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIDCD

    PROJECT SUMMARYDespite recent advances in cancer therapiesplatinum based drugs are still widely used for the treatment of solid tumorsA primary example is cisplatinwhich is frequently used to treat lungbladdertesticularand cervical cancersHoweverlimitations of this therapy include the development of drug resistance in cancer cells as well as severe side effectssuch as nephrotoxicity and neurotoxic ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Biologically Targeted Vaccine for Chikungunya

    SBC: PRECISION VIROLOGICS INC            Topic: NIAID

    PROJECT SUMMARY ABSTRACT Chikungunya virusCHIKVis a mosquito transmitted alphavirus that causes explosive epidemics of a severe febrile illness characterized by debilitating polyarthralgia in humansCHIKV caused an estimatedmillion new cases in India alone inand has the potential to spread globally because of the distribution and abundance of its mosquito vectorsAedes aegypti and Aedes albopictusDu ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. A Novel Two-in-One Approach to Administer Surfactant and Provide Airway Support to VLBW Infants

    SBC: BB MEDICAL SURGICAL, INC.            Topic: NICHD

    PROJECT SUMMARYABSTRACT Every yearvery low birth weightVLBWandltginfants are born in the U SThe use of surfactant dramatically decreases morbidity and mortality due to respiratory distress syndromeRDSin VLBW infantsCurrent standards for surfactant administration require the infant to be intubatedso that surfactant can be delivered to the trachea and lungsIntubating a VLBW infant is challenging and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Ultra-sensitive Rapid Diagnostic Test to Support the End-Game of the Global Program to Eliminate Lymphatic Filariasis

    SBC: NANOCOMPOSIX, INC.            Topic: NIAID

    Project SummaryAbstract Lymphatic filariasisLFcaused by the parasitic filarial worm Wuchereria bancroftiis a disfiguring and debilitating neglected tropical disease that affectsmillion people incountriesThrough the World Health Organization sWHOGlobal Program for the Elimination of Lymphatic FilariasisGPELFbillion drug regimens have been distributed via mass drug administrationMDAtomillion people ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Software for Determining Proteoform Heterogeneity and Protein Expression Fidelity

    SBC: GENNEXT TECHNOLOGIES, INC.            Topic: 400

    The importance of large protein drugsbiopharmaceuticalsand their generic counterpartsknown as biosimilarshas created a need for improved analytics to facilitate biopharmaceutical research and to combat adverse drug reactionsThe recombinant protein expression process is inherently prone to low level errors resulting in sequence variants caused by amino acid misincorporationwhich are observed in bot ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a bioconjugate vaccine against Group B Streptococcus

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Streptococcus agalactiaecommonly referred to as Group B StreptococcusGBSis a leading cause of neonatal meningitis and sepsis worldwide as well as an agent of invasive disease in both pregnant and non pregnant adultsGBS neonatal disease manifests as early onsetdefined as disease within the first six days after birthor late onsetdefined as disease occurring after the first week of li ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction

    SBC: Renova Therapeutics, Inc.            Topic: NHLBI

    ABSTRACT TypeDiabetes MellitusT DMaffectsmillion patients in US withnew patients annuallyLifespan is shortenedyearsdue to kidney and heart diseaseTight glucose control reduces microvascular complications and adverse cardiovascular eventsInsulin therapy is essential for such patientsbut has shortcomingsaonlyinpatients achieve targeted glucose controlHbA c andltbaggressive insulin therapy increases ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Integrated Microbial Screening and Antimicrobial Susceptibility Test on Microfluidic Digital Array for Diagnosis of Urinary Tract Infections

    SBC: Combinati Incorporated            Topic: NIAID

    Abstract COMBiNATi will work with Stanford University to bring the world s first integrated ID AST UTI diagnostic platform to the market by combining COMBiNATi sone clickcost effective dPCR platform with Stanford s pathogen identificationIDHRMA algorithm for broad detectiondeep characterization and absolute quantification of UTI pathogensBy the end of the Phaseprojectwe will deliver the prototype ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government